Anti-PD1 Monoclonal Antibody

BIOLOGICAL2 trials

Sponsors

Yuanquan Yang, City of Hope Medical Center

Conditions

Advanced Malignant Solid NeoplasmHematopoietic and Lymphatic System NeoplasmLung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

Phase 2

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

RecruitingNCT06470971

Yuanquan YangAdvanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm

Start: 2024-07-09End: 2030-12-31Target: 40Updated: 2026-01-20

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

RecruitingNCT07288034

City of Hope Medical CenterLung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

Start: 2026-04-08End: 2028-10-08Target: 535Updated: 2026-04-15

Related Papers

Siltuximab for the prevention of severe immune-related adverse events during immune checkpoint inhibitor rechallenge in advanced cancer: First interim analysis of the CIRES trial.

Journal of Clinical Oncology2026-05-28